Pure narrowband photon-pair generation in a monolithic cavity
Optics Express · 04.05.2026 · 34 (9) · 17334
DOI: 10.1364/oe.592005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Optics Express, online erschienen am 01.05.2026. Verfasst von Xavier Barcons Planas und 2 weiteren Autor:innen. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Forschung, Technologie und Raumfahrt.
Abstract (Originalsprache)
Photonic quantum technologies require efficient sources of pure single photons. We present a heralded single-photon source based on spontaneous parametric down-conversion in a monolithic cavity optimized for high spectral and spatial purity. The source heralds single photons at a wavelength of 1540 nm and a spectral bandwidth of 168 MHz, with a maximum heralding efficiency of 70% including all transmission and detection losses, while keeping the multi-photon contamination below 3%. The cavity enhancement predominantly generates photons into the central cavity mode, with a theoretical upper bound on the spectral purity of 79.4% arising from nonzero overlap with adjacent cavity modes. Spectral isolation of the central cavity mode with an etalon yields an increased measured spectral purity of (96.2±2.7)%.
Förderung
- Bundesministerium für Forschung, Technologie und Raumfahrt
Zitieren
APA
Barcons Planas, X., Chrzanowski, H. M., & Wolters, J. (2026). Pure narrowband photon-pair generation in a monolithic cavity. Optics Express, 34(9), 17334. https://doi.org/10.1364/oe.592005
Vancouver
Barcons Planas X, Chrzanowski HM, Wolters J. Pure narrowband photon-pair generation in a monolithic cavity. Optics Express. 2026;34(9):17334. doi:10.1364/oe.592005
BibTeX
@article{BarconsPlanas2026,
author = {Barcons Planas, Xavier and Chrzanowski, Helen M and Wolters, Janik},
title = {Pure narrowband photon-pair generation in a monolithic cavity},
journal = {Optics Express},
year = {2026},
volume = {34},
number = {9},
pages = {17334},
doi = {10.1364/oe.592005}
}
EUVIMED